Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality

  • Approximately 400 mothers and newborns die in Ethiopia each day1,2 partly due to health workers’ limited knowledge in the area of obstetrics
  • Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality
  • Sandoz is committed to increasing access to high-quality, affordable medicines, as well as healthcare services and education for mothers and children

Holzkirchen, Germany, March 2, 2015 – Sandoz today announced the launch of a new program, New Life & New Hope, to improve maternal and …

/by

Novartis announces completion of transactions with GSK

  • Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business
  • Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics
  • Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small molecules, positioning Novartis as a preferred partner for combination agents
  • Transactions expected to immediately lift core margins and further support overall …
/by

On World Cancer Day, Sandoz highlights global problem of child cancer

February 04, 2015 – Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and around 100,000 die from it each year. With proper diagnosis, treatment and drugs, most childhood cancers can be cured. In the developed countries, 80% of children survive, which is a great achievement in oncology treatment. However, in middle and low income countries, survival is estimated to drop to as low as 5%. Cancer is a leading cause of childhood deaths in these countries. This disparity is primarily because of lack of proper diagnosis and basic treatment …

/by

Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses

Basel, January 27, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “2014 was a transformational year for Novartis. We improved our execution, while taking steps to focus the company on our three leading businesses with global scale. We delivered solid sales growth with margin expansion, strengthened innovation, and advanced our quality and productivity agendas. I’m confident that we are positioned for future success.”

  • Net sales grew in FY 2014, with strong core[1] margin expansion
    • Net sales increased 1% (+3% cc[1 …
/by

Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee

  • Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US
  • Biosimilar filgrastim recommended to be approved for use in all requested indications
  • Committee’s recommendation based on review of extensive data from analytical, non-clinical, clinical studies and post-marketing pharmacovigilance

Holzkirchen, January 7, 2015 – Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its …

/by

Sandoz launches authorized generic version of Vivelle-Dot®

Princeton, New Jersey, December 22, 2014 – Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot®, which is marketed by Novartis Pharmaceuticals Corporation.

Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.

“We are pleased to partner with our colleagues at NPC to further expand our offering of affordable, high-quality medicines,” said Peter Goldschmidt, President of Sandoz Inc.

According to …

/by

Sandoz Brazil launches Tadalafil, first generic version of Cialis® to treat erectile dysfunction

  • Licensing agreement with Eli Lilly enables Sandoz to commercialize and distribute Cialis® in the Brazilian market

Sao Paulo, December 18, 2014 – Sandoz, the generics pharmaceutical division of Novartis, announces today that it is launching Tadalafil, a generic version of Cialis®, indicated to treat patients with erectile dysfunction. With the launch, Sandoz will be the first pharmaceutical company to market a generic version of Cialis® in Brazil.

Tadalafil is the result of a trade agreement with Eli Lilly Brazil®, which allows Sandoz to commercialize …

/by

Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

  • Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer
  • PIONEER data supported filing for biosimilar filgrastim in the US
  • The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

Holzkirchen, December 8, 2014 – Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim …

/by

Novartis Africa Day highlights company’s efforts to expand access to healthcare

Basel, December 05, 2014 – Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company’s Malaria Initiative.

  • Africa’s healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise
  • In addition to existing corporate responsibility efforts such as its Malaria …
/by

Today is International Day of People with Disabilities

December 03, 2014 – Established in 1992, International Day of People with Disabilities is a United Nations sanctioned day that aims to promote an understanding of people with disabilities and encourage support for their dignity, rights and well-being.

People with disabilities often face barriers, including physical, social, economic, educational, attitudinal and health care barriers. There are many types of disabilities and impairments, both visible and invisible.

More than 1 billion people live with a disability, says the world report on disability, published …

/by